Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Microbiome make or break time for MaaT Pharma
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
